{"id":"baraclude-tab","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Lactic acidosis (rare but serious)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Entecavir is a nucleoside analog that selectively inhibits HBV polymerase (reverse transcriptase), preventing the virus from copying its genetic material and reducing viral load. It has high specificity for HBV and minimal activity against human reverse transcriptase, making it well-tolerated for chronic hepatitis B treatment.","oneSentence":"Baraclude (entecavir) inhibits hepatitis B virus reverse transcriptase, blocking viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:28:12.932Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection in adults"},{"name":"Chronic hepatitis B infection in children and adolescents"}]},"trialDetails":[{"nctId":"NCT04942886","phase":"NA","title":"Prophylactic Entecavir for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation","status":"ENROLLING_BY_INVITATION","sponsor":"Seoul St. Mary's Hospital","startDate":"2021-08-21","conditions":"Hepatitis B Reactivation, Hematopoietic Stem Cell Transplantation, Antiviral Drug","enrollment":226},{"nctId":"NCT02862548","phase":"PHASE2","title":"Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-09-16","conditions":"Chronic Hepatitis B","enrollment":51},{"nctId":"NCT02555943","phase":"PHASE2, PHASE3","title":"DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-02","conditions":"Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation","enrollment":23},{"nctId":"NCT03491553","phase":"PHASE2","title":"Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-04-06","conditions":"Chronic Hepatitis B","enrollment":48},{"nctId":"NCT03847246","phase":"NA","title":"Bioequivalence Study of Entecavir Tablets and Baraclude® Under Fasting Condition in Chinese Healthy Volunteers","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2018-12-04","conditions":"Chronic Hepatitis b","enrollment":26},{"nctId":"NCT01913431","phase":"PHASE4","title":"Baracle Tab. ® Versus Baraclude Tab.® for Patients With HBeAg Chronic Hepatitis B","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2013-09-12","conditions":"HBeAg-Positive Chronic Hepatitis B","enrollment":118},{"nctId":"NCT01341106","phase":"PHASE4","title":"Induction of Fibrosis Regression on Patients With Chronic Hepatitis B Infection","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2011-04","conditions":"Hepatitis B, Chronic, Liver Fibrosis","enrollment":7},{"nctId":"NCT02523547","phase":"PHASE4","title":"Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude","status":"UNKNOWN","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2015-01","conditions":"Chronic Hepatitis B","enrollment":134},{"nctId":"NCT01063036","phase":"PHASE3","title":"Efficacy and Safety Study of Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Who Failed Previous Treatment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-05","conditions":"Chronic Hepatitis B","enrollment":144}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Baraclude Tab.®","genericName":"Baraclude Tab.®","companyName":"Dong-A ST Co., Ltd.","companyId":"dong-a-st-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Baraclude (entecavir) inhibits hepatitis B virus reverse transcriptase, blocking viral replication. Used for Chronic hepatitis B infection in adults, Chronic hepatitis B infection in children and adolescents.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}